Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Semaglutide may do more than manage blood sugar — it's showing real promise for mental health. A large Swedish study found semaglutide was linked to a 21% lower risk of psychiatric hospitalization and a 17% lower risk of bipolar relapse hospitalization. Separate research also confirms GLP-1s don't raise suicide risk and may actually reduce psychiatric deterioration in people with depression or anxiety.
GLP-1 receptor agonists — best known for treating diabetes and obesity — are turning heads in psychiatry. A large Swedish observational study of nearly 15,000 patients with bipolar disorder (BD) and diabetes or obesity found that semaglutide was associated with significantly lower rates of psychiatric hospitalization compared to periods when the same patients weren't using the drug. The findings, published in Acta Psychiatrica Scandinavica, suggest semaglutide may work through direct effects on brain function, including neuroinflammation and the HPA axis, in addition to its metabolic benefits.
The psychiatric signal extends beyond bipolar disorder. A separate Swedish national cohort study in Lancet Psychiatry found semaglutide was associated with a 42% lower risk of worsening mental illness in patients with depression or anxiety. And a Danish study in Molecular Psychiatry confirmed GLP-1s are not linked to increased suicide risk — and may actually lower it compared to DPP-4 inhibitors.
By the Numbers:
Why it matters: These converging findings from multiple large studies suggest GLP-1s — particularly semaglutide — may have meaningful neuropsychiatric benefits beyond their metabolic effects. While experts caution that randomized trials are needed before clinical adoption, the signal is strong enough to prompt a rethink of how these drugs are considered for patients with comorbid psychiatric conditions.
